Drugs /

ramucirumab

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

Generic Name(s):
ramucirumab
Trade Name(s):
Cyramza
NCI Definition [1]:
A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells.

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for ramucirumab

Ramucirumab has been investigated in 48 clinical trials, of which 40 are open and 8 are closed. Of the trials investigating ramucirumab, 9 are phase 1 (6 open), 9 are phase 1/phase 2 (7 open), 27 are phase 2 (24 open), 1 is phase 2/phase 3 (1 open), and 2 are phase 3 (2 open).

EGFR Exon 19 Deletion, EGFR L858R, and EGFR A763_Y764insFQEA are the most frequent biomarker inclusion criteria for ramucirumab clinical trials.

Adenocarcinoma of the gastroesophageal junction, gastric adenocarcinoma, and non-small cell lung carcinoma are the most common diseases being investigated in ramucirumab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ramucirumab
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Ramucirumab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ramucirumab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,931 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
imc-1121b, Cyramza, monoclonal antibody hgs-etr2, anti-vegfr-2 fully human monoclonal antibody imc-1121b, anti-vegfr-2 fully human monoclonal antibody imc-1121b, immunoglobulin g1, anti-(vascular endothelial growth factor receptor 2 (ec 2.7.10.1 or protein-tyrosine kinase receptor flk-1 or cd309 antigen) extracellular domain); human monoclonal imc-1121b γ1 heavy chain (219-214')-disulfide with human monoclonal imc-1121b κ light chain (225-225'':228-228'')-bisdisulfide dimer, imc 1121b, ly3009806, immunoglobulin g1, anti-(human vascular endothelial growth factor receptor type vegfr-2 extracellular domain) (human monoclonal imc-1121b γ-chain), disulfide with human monoclonal imc-1121b κ-chain, dimer, imc1121b, ramucirumab (substance), ramucirumab, ramucirumab (product), ramucirumab
Drug Categories [2]:
Therapeutic antibodies
Drug Target(s) [2]:
KDR
NCIT ID [1]:
C70792
SNOMED ID [1]:
R-FC1C3

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.